Literature DB >> 8613066

Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses.

A Villanueva1, G Reyes, M Cuatrecasas, A Martínez, N Erill, E Lerma, A Farré, F Lluís, G Capellá.   

Abstract

BACKGROUND & AIMS: Mutations at codon 12 of the K-ras gene are present in 65%-100% of carcinomas of human exocrine pancreas and could be used as a potential tumor marker at the tissue level. The purpose of this study was to assess, in large series of patients, the utility of K-ras mutation analysis to evaluate fine-needle aspirates of pancreatic masses.
METHODS: One hundred fifteen fine-needle aspirates obtained from 93 patients were evaluated retrospectively. Cytological analysis was based on the review of cell blocks. Mutations were detected by using artificial restriction fragment length polymorphisms using the Hphl and BstNl approaches.
RESULTS: The sensitivity and specificity of cell block cytology was 64% and 100%, respectively, for the diagnosis of pancreatic carcinoma. K-ras mutations were detected in 41 pancreatic carcinomas (sensitivity, 59%) and in one mucinous cystic tumor; specificity of ras analysis alone was 100%. The sensitivity of cytology combined with K-ras mutations were 77.6% and 100%, respectively.
CONCLUSIONS: The detection of K-ras mutations would have suggested the diagnosis of pancreatic cancer in 14 cases otherwise not detected by cytology alone. K-ras mutation analysis should be restricted to cell blocks containing suspicious, normal-appearing duct cells, or insufficient material in the cytological examination.

Entities:  

Mesh:

Year:  1996        PMID: 8613066     DOI: 10.1053/gast.1996.v110.pm8613066

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Detection of k-ras gene point mutation in fine needle aspiration and pancreatic juice by sequence special primer method and its clinical significance.

Authors:  Xun-Liang Liu; Cun-Cai Dai; Yi Miao; Jing-Hui Du; Zhao-Song Zhang; Shu-Zhen Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum.

Authors:  L Theodor; E Melzer; M Sologov; G Idelman; E Friedman; S Bar-Meir
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

3.  Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.

Authors:  Lucy A Parker; Miquel Porta; Blanca Lumbreras; Tomàs López; Luisa Guarner; Ildefonso Hernández-Aguado; Alfredo Carrato; Josep M Corominas; Juli Rifà; Esteve Fernandez; Joan Alguacil; Núria Malats; Francisco X Real
Journal:  Eur J Epidemiol       Date:  2011-02-06       Impact factor: 8.082

4.  [Indications for pancreatic biopsy. Uncommon, but increasingly more important].

Authors:  J-M Löhr; G Klöppel
Journal:  Pathologe       Date:  2005-02       Impact factor: 1.011

5.  Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures.

Authors:  J C Saurin; M O Joly-Pharaboz; P Pernas; L Henry; T Ponchon; J J Madjar
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 6.  K-Ras mutations and benign pancreatic disease.

Authors:  M Löhr; P Maisonneuve; A B Lowenfels
Journal:  Int J Pancreatol       Date:  2000-04

7.  K-ras mutations in the bile of patients with primary sclerosing cholangitis.

Authors:  S Kubicka; F Kühnel; P Flemming; B Hain; N Kezmic; K L Rudolph; M Manns; P N Meier
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

8.  Mutant KRAS is a druggable target for pancreatic cancer.

Authors:  Elina Zorde Khvalevsky; Racheli Gabai; Itzhak Haim Rachmut; Elad Horwitz; Zivia Brunschwig; Ariel Orbach; Adva Shemi; Talia Golan; Abraham J Domb; Eylon Yavin; Hilla Giladi; Ludmila Rivkin; Alina Simerzin; Rami Eliakim; Abed Khalaileh; Ayala Hubert; Maor Lahav; Yael Kopelman; Eran Goldin; Alan Dancour; Yael Hants; Sagit Arbel-Alon; Rinat Abramovitch; Amotz Shemi; Eithan Galun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas.

Authors:  D Bartsch; D Bastian; P Barth; A Schudy; C Nies; O Kisker; H J Wagner; M Rothmund
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

10.  K-ras gene mutation in the diagnosis of ultrasound guided fine-needle biopsy of pancreatic masses.

Authors:  Min Zheng; Lian-Xin Liu; An-Long Zhu; Shu-Yi Qi; Hong-Chi Jiang; Zhu-Ying Xiao
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.